FdaApplication
NDA 211801
Identifiers
- fda_app_no: NDA211801
Properties
| Property | Value |
|---|---|
| applicant_name | ARDELYX INC |
| application_type | NDA |
| approval_date | 2019-09-12 |
Revenue by product
IBSRELA
| Period | Revenue |
|---|---|
| Q2 2026 | $86.2M |
| Q1 2026 | $70.1M |
| Q4 2025 | $86.6M |
| Q3 2025 | $78.2M |
| Q2 2025 | $65.0M |
| Q1 2025 | $44.4M |
| Q4 2024 | $53.8M |
| Q3 2024 | $40.6M |
| Q2 2024 | $35.4M |
| Q1 2024 | $28.4M |
| Q4 2023 | $28.2M |
| Q3 2023 | $22.3M |
| Q2 2023 | $18.3M |
| Q1 2023 | $11.4M |
| Q4 2022 | $8.7M |
| Q3 2022 | $4.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| IBSRELA | TENAPANOR HYDROCHLORIDE | EQ 50MG BASE | TABLET;ORAL |
1 product